Organon Canada, in partnership with Shanghai Henlius Biotech, has launched two new denosumab biosimilars in Canada: BILDYOS® (60 mg/1 mL) and TUZEMTY® (120 mg/1.7 mL), expanding Organon’s biosimilars portfolio to eight products across five therapeutic areas. These medications, which treat osteoporosis and bone-related events in cancer patients, aim to improve treatment access and reduce healthcare costs for Canadians. The launch underscores Organon’s commitment to enhancing women’s health and providing more treatment options, particularly for the 2.3 million Canadians affected by osteoporosis.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/organon-canada-and-henlius-expand-access-to-denosumab-treatments-with-launch-of-bildyos-denosumab-injection-and-tuzemty-denosumab-injection-biosimilars-to-prolia-and-xgeva
